Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TAK
TAK logo

TAK Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
17.720
Open
17.660
VWAP
17.61
Vol
3.31M
Mkt Cap
55.44B
Low
17.550
Amount
58.33M
EV/EBITDA(TTM)
10.25
Total Shares
3.16B
EV
12.88T
EV/OCF(TTM)
12.01
P/S(TTM)
1.97
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.
Show More

Events Timeline

(ET)
2026-04-05
21:20:00
Denali Therapeutics Regains Full Control of DNL593
select
2026-04-01 (ET)
2026-04-01
16:20:00
Abivax Appoints Michael Nesrallah as Chief Commercial Officer
select
2026-04-01
07:30:00
Axsome Acquires Exclusive Global Rights to Takeda's TAK-063
select
2026-03-29 (ET)
2026-03-29
11:00:00
Takeda Announces New Data on Zasocitinib
select

News

stocktwits
9.5
04-13stocktwits
Spyre Therapeutics' Trial Data Boosts Stock by 23%
  • Significant Stock Surge: Shares of Spyre Therapeutics Inc. (SYRE) soared 23% on Monday, marking its largest single-day gain since June 2023, driven by positive ulcerative colitis trial data that highlighted the drug's potential effectiveness.
  • Trial Results Stand Out: The company reported that its SPY001 phase 2 trial met its primary endpoint with a statistically significant reduction in disease activity, and the drug was well tolerated, although six subjects experienced treatment-emergent adverse events, indicating a need for ongoing safety monitoring.
  • Analyst Optimism: Analysts from TD Cowen and Leerink raised their price targets for Spyre, with TD Cowen increasing it to $80 and Leerink to $106 from $49, reflecting heightened confidence in SPY001's success in treating ulcerative colitis and Crohn's disease.
  • Retail Investor Sentiment Shift: On Stocktwits, retail sentiment around SYRE stock shifted from 'neutral' to 'extremely bullish' within 24 hours, with message volume increasing from 'high' to 'extremely high', indicating strong investor confidence in Spyre's future performance.
moomoo
7.5
04-03moomoo
Takeda Ends Collaboration Agreement with Denali Therapeutics on DNL593
  • Collaboration Agreement: Denali Therapeutics has entered into a collaboration agreement with DNL593, focusing on the development of therapeutic solutions.

  • Research Focus: The partnership aims to advance research and development in the field of neuroscience, leveraging Denali's expertise and resources.

NASDAQ.COM
8.5
04-03NASDAQ.COM
Biotech Landscape Update: Regulatory Approvals and Acquisitions
  • ARS Pharma Expands Neffy Label: ARS Pharmaceuticals received FDA approval to update the Neffy 1mg label, removing age restrictions for individuals weighing over 33 lbs, which is expected to significantly boost market demand and enhance the company's competitive edge in allergy treatment.
  • Novo Nordisk Wins Approval for Awiqli: Novo Nordisk's Awiqli (insulin icodec-abae) received FDA approval as the first once-weekly basal insulin, with a U.S. launch planned for 2H 2026, strengthening the company's leadership in diabetes care.
  • Biogen Acquires Apellis: Biogen has agreed to acquire Apellis for $41 per share, valuing the deal at approximately $5.6 billion, which is expected to enhance its market share in immunology and rare diseases while driving future revenue growth.
  • Takeda's Zasocitinib Clinical Trial Success: Takeda's Zasocitinib showed that about 70% of patients achieved significant skin clearance in Phase 3 trials, with plans to submit a New Drug Application in 2026, further solidifying its position in the dermatology market.
NASDAQ.COM
8.5
04-01NASDAQ.COM
Axsome Acquires Global Rights to TAK-063 from Takeda
  • Asset Purchase Agreement: Axsome Therapeutics has signed an asset purchase agreement with Takeda Pharmaceutical to acquire exclusive global rights to TAK-063 (balipodect), further expanding its leading CNS portfolio and demonstrating strategic positioning in neuropsychiatric treatment.
  • Clinical Trial Plans: Axsome intends to initiate Phase 3 trial-enabling activities for schizophrenia in 2026, indicating strong confidence in the development of balipodect and aiming to improve treatment outcomes for patients through this novel mechanism.
  • Clinical Trial Results: Balipodect has shown positive results in a 164-patient proof-of-concept Phase 2 trial for schizophrenia and has demonstrated a favorable safety and tolerability profile in clinical studies involving over 360 individuals, enhancing its market potential.
  • Financial Arrangement: Under the agreement, Axsome obtains worldwide commercial, development, and manufacturing rights to balipodect, while Takeda receives an upfront payment and is eligible for additional payments related to development, regulatory, and commercial milestones, as well as royalties on potential global net sales, ensuring mutual benefit.
Newsfilter
8.5
03-31Newsfilter
Eli Lilly to Acquire Centessa Pharmaceuticals for Up to $7.8 Billion
  • Acquisition Scale: Eli Lilly has agreed to acquire Centessa Pharmaceuticals for up to $7.8 billion, with an upfront payment of $38 per share representing a 38% premium over Monday's closing price, which will further solidify Lilly's leadership in the neuroscience sector.
  • Drug Development Potential: The orexin agonists being developed by Centessa are expected to treat narcolepsy and other neurological conditions associated with drowsiness, with a market potential estimated between $15 billion and $20 billion, significantly enhancing Lilly's product portfolio if successfully launched.
  • Market Competition Landscape: Although Centessa's drug is not expected to receive FDA approval until 2028, its competitor Taked's similar drug is under review, indicating the intense competition in the market, prompting Lilly to accelerate its development efforts to maintain its lead.
  • Strategic Investment Direction: Lilly plans to leverage cash flows from its best-selling drugs Zepbound and Mounjaro for further investments, having recently announced acquisitions of cell therapy company Orna Therapeutics and inflammation-focused Ventyx Biosciences, demonstrating its commitment to expanding its product line.
CNBC
8.5
03-31CNBC
Eli Lilly to Acquire Centessa Pharmaceuticals for Up to $7.8 Billion
  • Acquisition Scale: Eli Lilly has agreed to acquire Centessa Pharmaceuticals for up to $7.8 billion, with an upfront payment of $38 per share, totaling $6.3 billion, representing a 38% premium over Monday's closing price, reflecting strong confidence in the new drug development.
  • Market Potential: Oppenheimer analysts estimate that the market for orexin agonists targeting excessive daytime sleepiness could reach $15 billion to $20 billion, positioning Lilly to capture significant market share if Centessa's drugs gain FDA approval.
  • Optimistic R&D Outlook: Although Centessa's drug is not expected to be approved until 2028, mid-stage trial data suggests it could become the best-in-class treatment, further solidifying Lilly's leadership in neuroscience.
  • Strategic Investment Direction: Lilly plans to leverage cash flow from its best-selling drugs Zepbound and Mounjaro to continue expanding its product line, having recently announced acquisitions of cell therapy company Orna Therapeutics and inflammation-focused Ventyx Biosciences, indicating a proactive approach in the biopharmaceutical sector.
Wall Street analysts forecast TAK stock price to rise
1 Analyst Rating
Wall Street analysts forecast TAK stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
18.00
Averages
18.00
High
18.00
Current: 0.000
sliders
Low
18.00
Averages
18.00
High
18.00
Bernstein
Market Perform
to
Outperform
upgrade
AI Analysis
2026-04-08
Reason
Bernstein
Price Target
AI Analysis
2026-04-08
upgrade
Market Perform
to
Outperform
Reason
Bernstein upgraded Takeda to Outperform from Market Perform with a price target of 6,900 yen, up from 5,100 yen, citing \"bold\" cost cuts and multiple upcoming de-risking events for the pipeline.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$97
2025-12-30
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$97
2025-12-30
maintain
Buy
Reason
H.C. Wainwright says Xoma (XOMA) took "a nice ride down the creativity road again with nice pipeline expansion," after the company announced an expanded relationship with partner Takeda (TAK). The deal with Takeda is highlighted by no cash out from Xoma for bringing in nine assets, the firm notes. This was accomplished by only marginally reducing Xoma's royalty/milestone share in Takeda's mezagitamab. Wainwright maintains its positive view here on the depth and breadth of Xoma's partnered assets as well as the ongoing creativity of transaction the company consummates, and looks forward to a transactional and royalty growing 2026. The firm has a Buy rating on Xoma with a price target of $97 on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for TAK
Unlock Now

Valuation Metrics

The current forward P/E ratio for Takeda Pharmaceutical Co Ltd (TAK.N) is 12.39, compared to its 5-year average forward P/E of 26.71. For a more detailed relative valuation and DCF analysis to assess Takeda Pharmaceutical Co Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
26.71
Current PE
12.39
Overvalued PE
39.90
Undervalued PE
13.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
9.01
Current EV/EBITDA
3.41
Overvalued EV/EBITDA
10.90
Undervalued EV/EBITDA
7.12

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.47
Current PS
0.01
Overvalued PS
1.86
Undervalued PS
1.08

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

insiders buying stocks
Intellectia · 1172 candidates
Market Cap: >= 1000.00MPrice: >= $5.00Quarterly Insider Trading Dollar Volume: >= 0Monthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
TAK logo
TAK
Takeda Pharmaceutical Co Ltd
56.30B
KSPI logo
KSPI
Kaspi.kz AO
15.10B
CEPU logo
CEPU
Central Puerto SA
2.42B
RY logo
RY
Royal Bank of Canada
242.44B
BK logo
BK
Bank of New York Mellon Corp
88.88B
TSM logo
TSM
Taiwan Semiconductor Manufacturing Co Ltd
1.92T
large cap taht is basing
Intellectia · 14 candidates
Market Cap: >= 10.00BRsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Month Price Change Pct: $-5.00 - $5.00Support Resistance Relationship: PriceAroundSupport
Ticker
Name
Market Cap$
top bottom
JNJ logo
JNJ
Johnson & Johnson
574.36B
AMGN logo
AMGN
Amgen Inc
189.44B
PFE logo
PFE
Pfizer Inc
153.13B
WMB logo
WMB
Williams Companies Inc
88.95B
WBD logo
WBD
Warner Bros Discovery Inc
68.79B
TAK logo
TAK
Takeda Pharmaceutical Co Ltd
57.12B
what stocks to buy today by swing max
Intellectia · 30 candidates
Region: USPrice: $5.00 - $150.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Week Predict Return: >= 5.0%Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
BFAM logo
BFAM
Bright Horizons Family Solutions Inc
4.21B
GLRE logo
GLRE
Greenlight Capital Re Ltd
563.79M
RILY logo
RILY
BRC Group Holdings Inc
214.47M
BOX logo
BOX
Box Inc
3.37B
FTS logo
FTS
Fortis Inc
29.71B
NTES logo
NTES
NetEase Inc
75.69B
ANY STOCK FROM 5 TO 20.00
Intellectia · 1059 candidates
Region: USPrice: $5.00 - $20.00List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
MUFG logo
MUFG
Mitsubishi UFJ Financial Group Inc
202.67B
SAN logo
SAN
Banco Santander SA
185.79B
MFG logo
MFG
Mizuho Financial Group Inc
105.35B
PBR logo
PBR
Petroleo Brasileiro SA Petrobras
92.03B
ITUB logo
ITUB
Itau Unibanco Holding SA
91.41B
NU logo
NU
Nu Holdings Ltd
87.41B
us stock between $0.1 and $20
Intellectia · 2503 candidates
Price: $0.10 - $20.00List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
MUFG logo
MUFG
Mitsubishi UFJ Financial Group Inc
206.98B
SAN logo
SAN
Banco Santander SA
178.90B
MFG logo
MFG
Mizuho Financial Group Inc
104.37B
PBR logo
PBR
Petroleo Brasileiro SA Petrobras
87.06B
ITUB logo
ITUB
Itau Unibanco Holding SA
86.67B
NU logo
NU
Nu Holdings Ltd
83.54B
show stock below $20 and are marked bullish
Intellectia · 1002 candidates
Price: <= $20.00Option Sentiments: Bullish
Ticker
Name
Market Cap$
top bottom
LYG logo
LYG
Lloyds Banking Group PLC
81.38B
ET logo
ET
Energy Transfer LP
60.60B
TAK logo
TAK
Takeda Pharmaceutical Co Ltd
51.17B
BSBR logo
BSBR
Banco Santander Brasil SA
50.00B
ASX logo
ASX
ASE Technology Holding Co Ltd
41.24B
NOK logo
NOK
Nokia Oyj
35.71B
acciones por debajo 20 dolares
Intellectia · 3008 candidates
Price: <= $20.00
Ticker
Name
Market Cap$
top bottom
MUFG logo
MUFG
Mitsubishi UFJ Financial Group Inc
206.98B
SAN logo
SAN
Banco Santander SA
178.90B
MFG logo
MFG
Mizuho Financial Group Inc
104.37B
PBR logo
PBR
Petroleo Brasileiro SA Petrobras
87.06B
ITUB logo
ITUB
Itau Unibanco Holding SA
86.67B
NU logo
NU
Nu Holdings Ltd
83.54B
price between 1 and 20
Intellectia · 2629 candidates
Price: $1.00 - $20.00
Ticker
Name
Market Cap$
top bottom
MUFG logo
MUFG
Mitsubishi UFJ Financial Group Inc
206.98B
SAN logo
SAN
Banco Santander SA
178.90B
MFG logo
MFG
Mizuho Financial Group Inc
104.37B
PBR logo
PBR
Petroleo Brasileiro SA Petrobras
87.06B
ITUB logo
ITUB
Itau Unibanco Holding SA
86.67B
NU logo
NU
Nu Holdings Ltd
83.54B
any cheaper stocks for option strategies
Intellectia · 1234 candidates
Price: <= $20.00Weekly Average Turnover: >= 1,000,000Is Optionable: True
Ticker
Name
Market Cap$
top bottom
MUFG logo
MUFG
Mitsubishi UFJ Financial Group Inc
206.98B
SAN logo
SAN
Banco Santander SA
178.90B
MFG logo
MFG
Mizuho Financial Group Inc
104.37B
PBR logo
PBR
Petroleo Brasileiro SA Petrobras
87.06B
ITUB logo
ITUB
Itau Unibanco Holding SA
86.67B
NU logo
NU
Nu Holdings Ltd
83.54B
cheap stocks that are safe to daytrade
Intellectia · 54 candidates
Price: <= $20.00Relative Vol: >= 1.50Beta: LowRiskWeekly Average Turnover: >= 1,000,000Is Optionable: True
Ticker
Name
Market Cap$
top bottom
PBR logo
PBR
Petroleo Brasileiro SA Petrobras
87.06B
ITUB logo
ITUB
Itau Unibanco Holding SA
86.67B
VALE logo
VALE
Vale SA
66.46B
TAK logo
TAK
Takeda Pharmaceutical Co Ltd
51.17B
BSBR logo
BSBR
Banco Santander Brasil SA
50.00B
BBD logo
BBD
Banco Bradesco SA
39.45B

Whales Holding TAK

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Takeda Pharmaceutical Co Ltd (TAK) stock price today?

The current price of TAK is 17.55 USD — it has decreased -1.52

What is Takeda Pharmaceutical Co Ltd (TAK)'s business?

Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.

What is the price predicton of TAK Stock?

Wall Street analysts forecast TAK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TAK is18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Takeda Pharmaceutical Co Ltd (TAK)'s revenue for the last quarter?

Takeda Pharmaceutical Co Ltd revenue for the last quarter amounts to 1.19T USD, increased 4.16

What is Takeda Pharmaceutical Co Ltd (TAK)'s earnings per share (EPS) for the last quarter?

Takeda Pharmaceutical Co Ltd. EPS for the last quarter amounts to 65.65 USD, increased 337.08

How many employees does Takeda Pharmaceutical Co Ltd (TAK). have?

Takeda Pharmaceutical Co Ltd (TAK) has 47455 emplpoyees as of April 21 2026.

What is Takeda Pharmaceutical Co Ltd (TAK) market cap?

Today TAK has the market capitalization of 55.44B USD.